University of Pittsburgh Cancer Institute
Welcome,         Profile    Billing    Logout  
 174 Trials 
123 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kirkwood, John M
ATLAS-IT-05, NCT04796194: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Active, not recruiting
2
20
Europe, US
LTX-315 in combination with pembrolizumab
Lytix Biopharma AS, Laboratory Corporation of America, OWL
Advanced Melanoma
12/24
12/24
NCT03743766: Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Completed
2
42
US
Relatlimab, BMS-986016, Nivolumab, BMS-936558, Relatlimab + Nivolumab, BMS-986016 and BMS-936558
John Kirkwood, Bristol-Myers Squibb
Melanoma
07/24
07/24
NCT02535078 / 2015-002971-12: Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Checkmark OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Jun 2022 - Jun 2022: OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Withdrawn
1/2
113
US
Tebentafusp (IMCgp100)
Immunocore Ltd, AstraZeneca
Malignant Melanoma
06/23
09/23
NCT04370587: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting
1/2
64
US, RoW
T3011, T3011 + pembrolizumab
ImmVira Pharma Co. Ltd
Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
10/23
10/25
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Terminated
1/2
45
US, RoW
Modakafusp Alfa, TAK-573, Pembrolizumab
Takeda
Neoplasms, Melanoma
12/23
12/23
NCT04688658: Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Active, not recruiting
1/2
13
US
Nivolumab, Opdivo, AG013736, Duvelisib, Copiktra
John Kirkwood, Secura Bio, Inc., Bristol-Myers Squibb
Unresectable Melanoma
02/24
12/28
Ramanathan, Ramesh K
NCT01959139: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Completed
1/2
126
US
PEGPH20, Pegylated Recombinant Human Hyaluronidase, Oxaliplatin, Eloxatin, NSC-266046, Leucovorin, leucovorin calcium, Irinotecan, CPT-11, NSC-616348, 5-fluorouracil, 5-FU, Adrucil, NSC-19893
SWOG Cancer Research Network, National Cancer Institute (NCI), Halozyme Therapeutics
Metastatic Pancreatic Adenocarcinoma
04/19
11/23
NCT05074472: A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

Completed
1/2
35
US
ZB131
ZielBio, Inc.
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic, Ovarian Serous Cystadenocarcinoma
08/23
09/23
NCT02925689: Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Active, not recruiting
1
122
US, Canada
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436A, GSK2118436, Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Pharmacological Study
Mayo Clinic, GlaxoSmithKline, National Cancer Institute (NCI)
BRAF Gene Mutation, Hepatic Complication, Renal Failure, Solid Neoplasm
07/19
 
Edwards, Robert P
NCT03734692: Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Protocol-planned interim results readout for advanced recurrent ovarian cancer
Hourglass Nov 2023 - Nov 2023 : Data from P2 trial for recurrent platinum-sensitive ovarian cancer at SITC 2023
Checkmark Results from trial in combination with Ampligen
Mar 2022 - Mar 2022: Results from trial in combination with Ampligen
Recruiting
1/2
45
US
Rintatolimod, Ampligen, Pembrolizumab, Keytruda, Cisplatin, Platinol
Robert Edwards, AIM ImmunoTech Inc., Merck Sharp & Dohme LLC
Ovarian Cancer Recurrent
12/26
12/26
NCT02432378: Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Recruiting
1/2
25
US
Cisplatin + celecoxib + DC vaccine, Cisplatin + CKM + Celecoxib + DC Vaccine
Roswell Park Cancer Institute, AIM ImmunoTech Inc., National Cancer Institute (NCI), University of Pittsburgh
Cancer of Ovary, Cancer of the Ovary, Neoplasms, Ovarian, Ovarian Cancer, Ovary Cancer, Ovary Neoplasms
12/25
06/26
Socinski, Mark A
AdvanTIG-302, NCT04746924 / 2020-004985-21: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Active, not recruiting
3
662
Europe, Japan, US, RoW
Tislelizumab, BGB-A317, Ociperlimab, BGB-A1217, Pembrolizumab, KEYTRUDA, Placebo
BeiGene
Non-small Cell Lung Cancer, NSCLC
10/26
02/27
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting
3
600
Europe, Canada, US, RoW
Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere
OncoC4, Inc., BioNTech SE
Non Small Cell Lung Cancer
06/26
06/27
PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting
1/2
733
US, RoW
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez
OncoC4, Inc., National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
06/26
12/27
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
12/24
12/24
ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting
1
198
Europe, US, RoW
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1
Enliven Therapeutics
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
07/26
07/26
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing
N/A
Europe, Japan, US, RoW
Selpercatinib, LOXO-292, LY3527723
Eli Lilly and Company, Eli Lilly and Company
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
 
 
CYBRID-02, NCT05520099: Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Recruiting
N/A
216
US
Core Needle or Forceps Biopsy
Elephas, Hoosier Cancer Research Network
Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Cutaneous Melanoma, Endometrial Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
01/27
01/27
Long, G S
REACTION, NCT03610711: (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

Active, not recruiting
1/2
21
US
Nivolumab, Optivo, Relatlimab, anti-LAG3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Gastroesophageal Cancer, Immune Checkpoint Inhibition
12/25
12/25
Chatta, Gurkamal S
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NCT04064190: Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Withdrawn
2
48
US
Vactosertib(TEW-7197)/ Durvalumab
MedPacto, Inc., AstraZeneca
Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma
12/23
12/24
NCT02555189: Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Completed
1/2
46
US
Enzalutamide, Xtandi, MDV3100, 915087-33-1, ASP9785, Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-, Ribociclib, LEE011, 1211441-98-3, 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, Kisqali, LEE-011, Laboratory Biomarker Analysis, Pharmacological Study, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Biopsy, BIOPSY_TYPE, Bx, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT SCAN, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, nuclear magnetic resonance imaging, sMRI, Structural MRI
Sidney Kimmel Cancer Center at Thomas Jefferson University, Novartis, Prostate Cancer Clinical Trials Consortium
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v7
12/22
09/23
NCT02744287: Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Feb 2023 - Feb 2023: Early P1 data in patients with metastatic castration-resistant prostate cancer at ASCO-GU 2023
Checkmark Updated data from BP-012 trial
Oct 2020 - Oct 2020: Updated data from BP-012 trial
Checkmark From BP-012 trial in advanced solid tumors at ASCO 2019 [screenshot]
May 2019 - Jun 2019: From BP-012 trial in advanced solid tumors at ASCO 2019 [screenshot]
More
Suspended
1/2
151
US
BPX-601, Rimiducid, AP1903
Bellicum Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
10/25
02/26
PRESERVE-006, NCT05682443: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Recruiting
1/2
144
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody, Gotistobart, lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses., Pluvicto
OncoC4, Inc., Prostate Cancer Clinical Trials Consortium
Metastatic Castration-resistant Prostate Cancer
06/26
06/27
NCI-2018-02448, NCT03751436: Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Completed
1
10
US
Enzalutamide, ASP9785, MDV3100, Xtandi, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
Roswell Park Cancer Institute, AbbVie
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
07/22
08/23
Bahary, Nathan
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
NCT05766748: Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Recruiting
1/2
30
US
Azeliragon, TTP488
Cantex Pharmaceuticals
Metastatic Pancreatic Cancer
02/25
05/25
Bauman, Julie
NCT03153982: Ruxolitinib in Operable Head and Neck Cancer

Terminated
2
16
US
Ruxolitinib, Jakafi
University of California, San Francisco, Incyte Corporation
Head and Neck Squamous Cell Carcinoma
10/23
10/23
KEYNOTE-A78, NCT03978689: A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting
1
85
US
CUE-101, KEYTRUDA®, Pembrolizumab, Pembrolizumab
Cue Biopharma, Merck Sharp & Dohme LLC
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
11/24
05/25
Sun, Weijing
NCT03488667: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Active, not recruiting
2
40
US
Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
University of Kansas Medical Center, Merck Sharp & Dohme LLC
Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
04/24
04/25
daNIS-3, NCT04952753 / 2021-000553-40: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Completed
2
204
Europe, Canada, Japan, US, RoW
NIS793, Bevacizumab, Modified FOLFOX6, 5FU+Leucovorin+Oxaliplatin, FOLFIRI, 5FU+Leucovorin+Irinotecan, Tislelizumab, VDT482
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Colorectal Cancer
01/25
01/25
NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Active, not recruiting
2
27
US
Oxaliplatin, Irinotecan, Leucovorin, Panitumumab
Criterium, Inc., Amgen
Colorectal Cancer Metastatic
12/24
01/25
Gibson, Michael
NCT04471415 / 2020-002770-27: Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Terminated
2a
61
Europe, US, RoW
DRP-104, atezolizumab
Dracen Pharmaceuticals, Inc., Dracen Pharmaceuticals, Inc.
Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
03/23
03/23
NCT05945823: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Recruiting
2
66
Europe, US
Futibatinib, TAS-120, Pembrolizumab, MK-3475, KEYTRUDA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Irinotecan
Taiho Oncology, Inc.
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
01/25
05/25
PANTHEoN, NCT04892875: A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

Withdrawn
1
24
NA
Zimberelimab, AB122, Etrumadenant, AB928, Cisplatin, Radiation
Jennifer Choe, Arcus Biosciences, Inc.
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Oral Cavity Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Larynx Cancer, Pharynx Cancer, Hypopharynx Cancer, Hypopharynx Squamous Cell Carcinoma
12/25
12/26
TEAM-HF, NCT06526195: Trial to Evaluate Safety and Effectiveness of Mechanical Circulatory Support in Patients with Advancing Heart Failure

Recruiting
N/A
850
US
CardioMEMS HF System, CardioMEMS, CardioMEMS PA Sensor, HeartMate 3 Left Ventricular Assist System, HM3, Guideline Medical Directed Therapy, GDMT
Abbott Medical Devices
Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
09/29
09/32
NCT04198870: MitraClip REPAIR MR Study

Recruiting
N/A
500
Europe, Canada, US
MitraClip™ device implantation, Mitral Valve Repair Surgery
Abbott Medical Devices
Mitral Valve Regurgitation
04/26
04/34
LeAAPS, NCT05478304: Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Recruiting
N/A
6500
Europe, Canada, US
AtriClip LAA Exclusion System
AtriCure, Inc., Population Health Research Institute
Ischemic Stroke, Systemic Embolism
12/31
04/32
Villaruz, Liza
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
BA3011-002, NCT04681131 / 2022-000135-23: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Active, not recruiting
2
240
Europe, US, RoW
CAB-AXL-ADC, BA3011, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non-Small-Cell Lung Cancer
08/25
08/25
NCT05746481: Tiragolumab and Atezolizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Active, not recruiting
2
3
US
Tiragolumab, RO7092284, Atezolizumab, Tecentriq, RO5541267, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin
Liza Villaruz, MD, Genentech, Inc.
Non-small Cell Lung Cancer
08/24
08/26
NCT04739358: CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Terminated
1/2
2
US
Tepotinib, Tepmetko
Criterium, Inc., EMD Serono Research & Development Institute, Inc.
Advanced Non-Small Cell Lung Cancer With MET Mutations
06/23
06/23
BA3021-001, NCT03504488 / 2022-000137-17: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Completed
1/2
132
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/24
12/24
NCT04982224: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Recruiting
1/2
237
US
REGN5093-M114, Cemiplimab
Regeneron Pharmaceuticals
Advanced NSCLC
02/30
02/30
ON-5001, NCT06022029: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination with Cemiplimab in Patients with Advanced Solid Tumors and Lymphomas.

Recruiting
1
168
US, RoW
ONM-501, Cemiplimab, Libtayo
OncoNano Medicine, Inc.
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
04/26
08/26
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting
1
250
Europe, Canada, US, RoW
ADP adoptive cell therapy
Adaptimmune
Neoplasms
04/32
04/32
Tarhini, Ahmad
NCT04526730: Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Active, not recruiting
2
17
US
Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System, Electroporation
H. Lee Moffitt Cancer Center and Research Institute, OncoSec Medical Incorporated
Melanoma
06/28
06/28
NCT04869137: Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Active, not recruiting
2
26
US
Lenvatinib Oral Product, LENVIMA, Pembrolizumab, Keytruda
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC
Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin
09/25
09/26
NCT06295159: Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Recruiting
2
90
US
Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Ipilimumab, Yervoy
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
07/27
07/27
NCT04562129: IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Recruiting
2
29
US
Interleukin-2, Aldesleukin, Ipilimumab, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, Clinigen, Inc.
Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
08/25
11/29
NCT05170334: Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
Binimetinib, Mektovi, ARRY-162, Belinostat, Beleodaq
H. Lee Moffitt Cancer Center and Research Institute, Pfizer, Acrotech Biopharma Inc.
Metastatic Uveal Melanoma
09/25
12/25
NCT05524935: Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Recruiting
2
37
US
Pembrolizumab, Keytruda, Olaparib, AZD2281, KU-0059736, Lynparza
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC
Uveal Melanoma, Ocular Melanoma
07/26
07/26
NCT06121180: Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
ZIV-Aflibercept, Zaltrap, Eylea, Cemiplimab, Libtayo
H. Lee Moffitt Cancer Center and Research Institute, Genzyme, a Sanofi Company, Regeneron Pharmaceuticals
Metastatic Uveal Melanoma
10/30
10/30
KEYNOTE-E64, NCT04787042: Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Recruiting
1/2
316
US
ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], GAZYVA, pembrolizumab, KEYTRUDA®
Simcha IL-18, Inc., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
06/25
12/25
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
NCT04975152: Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Recruiting
1
30
US
Cemiplimab-Rwlc, Libtayo
H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals, Sanofi-Synthelabo
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
06/27
06/27
NCT03114319: Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Active, not recruiting
1
227
Europe, Canada, Japan, US, RoW
TNO155, TNO155 in combination with EGF816 (nazartinib)
Novartis Pharmaceuticals
Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma
05/25
05/25
C-1100-01, NCT04121676: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Completed
1
91
US
AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4
Agenus Inc.
Advanced Cancer
02/24
11/24
NCT04242147: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors

Terminated
1
45
US
KD033 (SAR445710)
Kadmon, a Sanofi Company
Solid Tumor
12/23
12/23
NCT04741997: Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Recruiting
1
50
US
Encorafenib Pill, Binimetinib Pill, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, Pfizer
Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
01/25
01/26
NCT05651828: Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Recruiting
1
34
US
Vismodegib 150 MG Oral Capsule, Erivedge
H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc.
Advanced Basal Cell Carcinoma
12/28
12/29
Ferris, Robert L
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
NCT03715946: Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Completed
2
40
US
Nivolumab Injection, BMS-936558, Radiotherapy (RT)
Robert L. Ferris, MD, PhD, Bristol-Myers Squibb
Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma
03/23
03/24
CA224-056, NCT04080804: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Recruiting
2
80
US
Nivolumab, anti-PD-1 antibody, OPDIVO®, Relatlimab, anti-LAG3 antibody, BMS-986016, Ipilimumab, anti-CTLA4 antibody, Yervoy ®
Dan Zandberg, Bristol-Myers Squibb
Head and Neck Squamous Cell Carcinoma (HNSCC)
05/26
09/26
Zanotti, Kristine M
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
NCT05113368: Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
2
31
US
Regorafenib, Fulvestrant
Sarah K. Lynam MD, Bayer
Ovarian Cancer, Serous Ovarian Cancer
06/25
12/25
Durie, Brian G
ASCENT, NCT03289299: Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Active, not recruiting
2
87
US
Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone
International Myeloma Foundation, Amgen, Janssen Scientific Affairs, LLC, Celgene, Trevie, Inc.
Smoldering Multiple Myeloma
09/23
11/31
Moschos, Stergios
ADAM, NCT03271372: Adjuvant Avelumab in Merkel Cell Cancer

Jan 2024 - Dec 2024: From trial
Active, not recruiting
3
101
US
Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Peripheral Blood Collection, Placebo, placebo therapy, PLCB, normal saline solution
University of Washington, EMD Serono
Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
04/26
02/29
NCT03089606: Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

Completed
2
27
US
FDG PET/CT scan, C11-AMT PET scan, Pembrolizumab, Keytruda, CT scan
UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Melanoma
04/21
07/23
NCT03765229: An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

Completed
2
11
US
Entinostat, Pembrolizumab, Keytruda
UNC Lineberger Comprehensive Cancer Center, Syndax Pharmaceuticals
Melanoma
12/22
07/23
NCT03620019: Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Completed
2
25
US
Denosumab, XGEVA, Pembrolizumab, Keytruda, Nivolumab, Opdivo
UNC Lineberger Comprehensive Cancer Center, Amgen
Melanoma Stage Iii, Melanoma Stage Iv, Melanoma, Melanoma (Skin), Cutaneous Melanoma
04/23
08/23
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
Brufsky, Adam M
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated
3
52
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
01/24
01/24
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
TBCRC 048, NCT03344965: Olaparib in Metastatic Breast Cancer

Active, not recruiting
2
114
US
Olaparib, AZD2281, KU-0059436
Beth Israel Deaconess Medical Center, Johns Hopkins University, AstraZeneca, Dana-Farber Cancer Institute
Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
07/25
12/25
HER2CLIMB-04, NCT04539938: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Active, not recruiting
2
70
US
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab deruxtecan, T-DXd, Enhertu, DS-8201
Seagen Inc.
HER2 Positive Breast Cancer
07/24
10/25
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Withdrawn
2
200
US
Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane
Veru Inc.
Metastatic Breast Cancer
03/24
05/24
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
09/24
07/27
S2007, NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
12/27
12/28
ETHAN, NCT05501704: - ET for Male BC

Recruiting
2
60
US
Tamoxifen, Nolvadex, Soltamox, Anastrozole, Arimidex, Degarelix, Abemaciclib, Verzenio
Jose Pablo Leone, Eli Lilly and Company, Translational Breast Cancer Research Consortium (TBCRC)
Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
04/26
04/36
VICC-NCBRE23172, NCT05919108: Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Recruiting
2
30
US
Endocrine Therapy, Biopsy of breast, Neratinib, Biospecimen Collection, Mammogram, Magnetic Resonance Imaging, Breast Surgery, Ultrasound
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Puma Biotechnology, Inc.
Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
04/30
04/31
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
04/25
09/25
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Ruddy, Kathryn
ETHAN, NCT05501704: - ET for Male BC

Recruiting
2
60
US
Tamoxifen, Nolvadex, Soltamox, Anastrozole, Arimidex, Degarelix, Abemaciclib, Verzenio
Jose Pablo Leone, Eli Lilly and Company, Translational Breast Cancer Research Consortium (TBCRC)
Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
04/26
04/36
Clump, David A
MIT-001, NCT04651634: for Prevention of CCRT-Induced OM in HNSCC Patients

Recruiting
2
60
US, RoW
MIT-001 plus CCRT
MitoImmune Therapeutics
Head and Neck Squamous Cell Carcinoma, Oral Mucositis
04/24
12/24
KEYSTROKE, NCT03546582: SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Recruiting
2
102
Canada, US
Pembrolizumab, Keytruda, Stereotactic Body Radiation Therapy (SBRT), SBRT
RTOG Foundation, Inc., Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma (HNSCC)
07/27
07/29
PREDICT, NCT03448926: The Registry:

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
Lee, James
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
NCT06196879: A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

Recruiting
2
436
Europe, Canada, Japan, US, RoW
Verekitug (UPB-101), Placebo
Upstream Bio Inc.
Severe Asthma
02/26
06/26
LUNG-MAP SUB-STUDY, NCT06031688: Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Recruiting
2
56
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, Tepotinib, c-Met Inhibitor MSC2156119J, EMD 1214063, EMD-1214063, EMD1214063, MSC2156119J
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, EMD Serono
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
05/28
05/29
NCT03952364: The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States

Recruiting
N/A
200
US
PredictSURE IBD™
PredictImmune Ltd, The Crohn's and Colitis Foundation
Crohn Disease, Ulcerative Colitis, IBD, Inflammatory Bowel Diseases
06/22
06/22
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
Palomba, Lia
NCT05397496: Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

Recruiting
1
140
Europe, Japan, US, RoW
PIT565
Novartis Pharmaceuticals
B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
06/27
06/28
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
 

Download Options